FOXO3 and breast cancer: In summary, sustained nuclear FOXO3a expression in breast cancer may culminate in cancer progression and the development of an aggressive phenotype similar to that observed in cytotoxic chemotherapy resistant breast cancer cell models and, can significantly attenuate their response to tamoxifen and cytotoxic chemotherapy.